• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration.

作者信息

Nakamagoe Kiyotaka, Tanaka Mayuko, Igari Kota

机构信息

Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305-8575, Japan.

Department of Neurology, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.

出版信息

Neurol Sci. 2023 Aug;44(8):2967-2970. doi: 10.1007/s10072-023-06754-4. Epub 2023 Mar 18.

DOI:10.1007/s10072-023-06754-4
PMID:36933100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10024277/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c445/10024277/593057f8396e/10072_2023_6754_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c445/10024277/593057f8396e/10072_2023_6754_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c445/10024277/593057f8396e/10072_2023_6754_Fig1_HTML.jpg

相似文献

1
Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration.在使用萨特利珠单抗治疗后，水通道蛋白4阳性视神经脊髓炎谱系障碍患者成功将泼尼松龙减量至每日3毫克以下的病例。
Neurol Sci. 2023 Aug;44(8):2967-2970. doi: 10.1007/s10072-023-06754-4. Epub 2023 Mar 18.
2
Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment.Satralizumab 治疗视神经脊髓炎谱系疾病引起的疼痛性阵挛发作完全缓解。
Intern Med. 2022 Sep 15;61(18):2785-2787. doi: 10.2169/internalmedicine.9036-21. Epub 2022 Feb 8.
3
Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient.一名阿根廷视神经脊髓炎谱系障碍患者使用萨特利珠单抗后出现严重发热性中性粒细胞减少症。
Mult Scler. 2023 Jan;29(1):150-153. doi: 10.1177/13524585221137231. Epub 2022 Nov 27.
4
Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.萨特利珠单抗治疗儿童发作性伴发作簇的视神经脊髓炎谱系障碍：一例报告
J Neurol. 2023 Oct;270(10):5085-5089. doi: 10.1007/s00415-023-11776-1. Epub 2023 May 19.
5
[Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder].[萨特利珠单抗抑制白细胞介素-6通路治疗视神经脊髓炎谱系障碍患者的本地经验]
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7. Vyp. 2):68-72. doi: 10.17116/jnevro202212207268.
6
Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.关于：依库珠单抗治疗水通道蛋白4阳性视神经脊髓炎谱系障碍的社论
Mult Scler Relat Disord. 2019 Aug;33:A1-A2. doi: 10.1016/j.msard.2019.07.001. Epub 2019 Jul 2.
7
Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.satralizumab：视神经脊髓炎谱系疾病的研究进展。
CNS Drugs. 2023 Apr;37(4):363-370. doi: 10.1007/s40263-023-00995-9. Epub 2023 Mar 18.
8
A safe change from eculizumab to satralizumab in a patient with neuromyelitis optica spectrum disorder.视神经脊髓炎谱系障碍患者从依库珠单抗安全转换为萨特利珠单抗。
Neurol Sci. 2023 Mar;44(3):1097-1098. doi: 10.1007/s10072-022-06495-w. Epub 2022 Nov 9.
9
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.视神经脊髓炎谱系疾病中 Satralizumab 的试验。
N Engl J Med. 2019 Nov 28;381(22):2114-2124. doi: 10.1056/NEJMoa1901747.
10
Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.使用 satralizumab 治疗视神经脊髓炎谱系疾病患者的真实世界管理：来自日本索赔数据库的结果。
Mult Scler Relat Disord. 2024 Apr;84:105502. doi: 10.1016/j.msard.2024.105502. Epub 2024 Feb 12.

引用本文的文献

1
Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan.日本视神经脊髓炎谱系障碍中用于视神经炎慢性治疗的生物制剂使用情况
Jpn J Ophthalmol. 2025 Jan;69(1):81-92. doi: 10.1007/s10384-024-01129-4. Epub 2024 Oct 29.

本文引用的文献

1
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.来自SAkuraSky和SAkuraStar研究的萨特利珠单抗治疗视神经脊髓炎谱系障碍（NMOSD）的长期安全性
Mult Scler Relat Disord. 2022 Oct;66:104025. doi: 10.1016/j.msard.2022.104025. Epub 2022 Jul 5.
2
Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.口服泼尼松维持疗法对水通道蛋白4抗体相关视神经脊髓炎谱系障碍的优化管理
Mult Scler Relat Disord. 2021 Apr;49:102750. doi: 10.1016/j.msard.2021.102750. Epub 2021 Jan 22.
3
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Satralizumab 单药治疗视神经脊髓炎谱系疾病的安全性和疗效：一项随机、双盲、多中心、安慰剂对照的 3 期临床试验。
Lancet Neurol. 2020 May;19(5):402-412. doi: 10.1016/S1474-4422(20)30078-8.
4
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.视神经脊髓炎谱系疾病中 Satralizumab 的试验。
N Engl J Med. 2019 Nov 28;381(22):2114-2124. doi: 10.1056/NEJMoa1901747.
5
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.视神经脊髓炎谱系障碍国际共识诊断标准
Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.